Physician

James Melvin Rajan, M.D.

According to 2025 Medicare claims, James Rajan, M.D. (NPI: 1922047067) practices nephrology in the Canton-Massillon, OH market, with the plurality of this provider's patient population coming from Stark, OH. This provider's primary affiliated billing organization is KIDNEY & HYPERTENSION CONSULTANTS, INC. (NPI: 1770524696; TIN: 34-1421578) and primary practice location at 44710-1702. Rajan is affiliated with the IHC Quality Partners, LLC (ACO ID: A2833) and ACO West Virginia (ACO ID: A3563), participating under the MSSP model.

Rajan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 372 traditional Medicare patients, billed 3,241 HCPCS/CPT codes, and received $172,764 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,291 prescription claims across 330 beneficiaries totaling $359,835 in drug costs, led by Farxiga (Dapagliflozin Propanediol). Open Payments data shows 77 records totaling $1,474. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $239,518 to $172,764. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $128,490 and ending at $359,835. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	488	16,979	$239,518
2016	568	12,891	$261,964
2017	606	6,527	$259,351
2018	586	9,394	$247,826
2019	551	7,914	$295,354
2020	444	4,950	$242,241
2021	456	4,767	$231,672
2022	381	3,277	$173,314
2023	383	4,169	$228,662
2024	372	3,241	$172,764

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	261	2,158	$128,490
2016	262	2,258	$118,216
2017	241	2,092	$215,452
2018	244	2,080	$125,107
2019	305	2,315	$280,522
2020	304	2,391	$892,701
2021	333	2,713	$750,370
2022	326	2,531	$143,211
2023	336	2,490	$168,213
2024	330	2,291	$359,835

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	110	114	$123
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	157	413	$84
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	107	172	$66
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	47	77	$57
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	36	36	$51

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	49	2,880	$51,457
Xphozah	Tenapanor Hcl	12	360	$33,028
Lokelma	Sodium Zirconium Cyclosilicate	35	1,482	$23,118
Calcitriol	Calcitriol	370	18,160	$6,165
Sevelamer Carbonate	Sevelamer Carbonate	30	1,035	$3,963

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	77	$1,474	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for James Melvin Rajan, M.D.?

Tedicare shows public-source Medicare data for James Melvin Rajan, M.D. (NPI 1922047067), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James Melvin Rajan, M.D. have ACO affiliation data?

James Melvin Rajan, M.D. is shown with ACO affiliation data for IHC Quality Partners, LLC (MSSP, ACO ID A2833) and ACO West Virginia (MSSP, ACO ID A3563).

What billing organization is linked to James Melvin Rajan, M.D.?

James Melvin Rajan, M.D. is linked to KIDNEY & HYPERTENSION CONSULTANTS, INC. (billing NPI 1770524696) in the available physician profile data.

Does James Melvin Rajan, M.D. have Open Payments data?

James Melvin Rajan, M.D. has 77 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.